WOW!!! That moved as if these guys invested in it.
Post# of 53536
WOW!!! That moved as if these guys invested in it... http://shakerzandmoverz.com/
NEW YORK, NY--(Marketwire -05/23/12)- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of competing companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Rosetta Genomics Ltd. ( ROSG ) and Osiris Therapeutics, Inc. ( OSIR ).
Access to the full company reports can be found at:
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a press release: "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, earlier this week announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview® mets2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview® mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient.
Osiris Therapeutics shares rose sharply after the company gained clearance to sell Prochymal in Canada. "This is the first regulatory approval of a stem-cell drug -- where the active ingredient of the drug is a stem cell -- in the world," Mills said. "It's a huge deal for us and a huge deal for the entire field of stem-cell therapy."
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
(0)
(0)